Navigation Links
Shining a light on heart disease
Date:5/1/2014

A study to investigate how nanoparticles could be used to improve the diagnosis and treatment of cardiovascular disease has received 3 million funding.

The project, led by the University of Strathclyde and involving researchers from the Universities of Glasgow and Warwick, is being supported by the Engineering and Physical Sciences Research Council (EPSRC).

Principal Investigator Professor Duncan Graham, Director of the Centre for Molecular Nanometrology at the University of Strathclyde, said: "Cardiovascular diseases cause more than a quarter of all deaths in the UK each year, and death rates from coronary heart disease are highest in Scotland.

"Estimates suggest the UK spends nearly 2 billion each year on healthcare costs of treating coronary heart disease our research combines nanotechnology with advanced statistical and biomedical research, focused on a clinical application which we hope will lead to a beneficial change in treatment of cardiovascular disease patients."

The research team will investigate atherosclerosis-related cardiovascular diseases (CVD), which are the leading cause of mortality in UK.

Currently, the risk of atherosclerosis in patients is identified by detecting specific inflammatory markers in the blood. However, atherosclerosis is characterised by inflammation localised in vessel walls and the researchers suspect it may be more beneficial to quantify vascular inflammation and to develop a method of delivering drugs directly to the diseased vessel.

To this end, the researchers will use nanoparticles small metallic particles which can be tagged onto other molecules which possess the ability to recognise inflammatory markers. The nanoparticles can then be detected by a technique called surface enhanced Raman scattering, whereby a light source is shone on the nanoparticles, transferring energy and causing them to vibrate.

The vibrations are detected and the strength of the signal provides an indication of the amount of nanoparticles and therefore inflammatory markers - present.

Dr Pasquale Maffia, senior lecturer in immunology at the University of Glasgow, said "Using this nanoparticle technology, the primary aim of the research is to develop a highly-sensitive but relatively affordable means of measuring inflammatory molecules in samples of atherosclerotic plaque from patients which could enable the clinician to forecast how the disease will progress."

It is hoped in the future that the nanoparticles can be further customised to enable the delivery of anti-inflammatory drugs.

Dr Maffia added: "The energetic vibrations could be harnessed as a drug release mechanism which could be time-controlled by the flick of a switch. The major advantage of this set-up is that the equipment is portable, so this novel nanoparticle diagnosis and treatment system could potentially be made accessible to anyone."

The funding award is part of the EPSRC Healthcare Technologies theme which plays a vital role in sponsoring basic research capabilities to create new techniques and technologies to address national and global health challenges.

The team involved in the project are: Professor Duncan Graham and Dr Karen Faulds, University of Strathclyde; Dr Pasquale Maffia, Professor Naveed Sattar, Professor Iain McInnes and Professor Paul Garside, University of Glasgow; and Professor Mark Girolami of the University of Warwick a composite of physical scientists who are specialists in nanoparticle technology, information technologists capable of interpreting and presenting data from complicated nanoparticle assays and clinical partners who are interested in how best to utilise this new information in improved healthcare practice.


'/>"/>

Contact: Lachlan Mackinnon
corporatecomms@strath.ac.uk
University of Strathclyde
Source:Eurekalert  

Related medicine news :

1. Shining the soothing light
2. Light activity every day keeps disability at bay
3. Model sheds new light on sports-related brain injuries
4. Study sheds light on how the immune system protects children from malaria
5. Let the sun shine in: Redirecting sunlight to urban alleyways
6. Bio-Rads Droplet Digital PCR technology highlighted at the 2014 AACR Annual Meeting
7. Good vibrations: Using light-heated water to deliver drugs
8. Daylight saving impacts the timing of heart attacks
9. High-tech materials purify water with sunlight
10. UV light aids cancer cells that creep along the outside of blood vessels
11. Ever-so-slight delay improves decision-making accuracy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Shining a light on heart disease
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: